First quarter in brief January – MarchFinancial summary for the first quarter and the period January – March 2022· Net sales amounted to SEK 0 million (SEK 0.0 million).· R&D costs amounted to SEK 10,6 million (8,2 million).· Operating...
Read MoreThe year in brief October – DecemberFinancial summary for the fourth quarter Net sales amounted to SEK 0 million (0,0 million). R&D costs amounted to SEK 12,9 million (11,2 million). Operating profit for the fourth quarter amounted to SEK...
Read MoreKancera AB (publ) today announces that Peter Selin has been appointed as Executive Vice President Corporate Development, responsible for business development, strategic partnerships and licensings. He will be part of the management team and report directly to the CEO.
Read MoreThis is a translation of press release in Swedish (2021-11-22). Kancera AB (Nasdaq First North Premier Growth Market: KAN) today presents preclinical results that show that KAND145 effectively reduces tumor size in a disease model of ovarian cancer. These...
Read MoreThis is a translation of a press release in Swedish published 2021-11-18. Kancera AB (Nasdaq First North Premier Growth Market: KAN) presents results from the exploratory phase IIa study with KAND567 in patients with COVID-19. The randomized double-blinded study...
Read More